L-Palmitoylcarnitine
|
Basic information |
| Metabolite name | L-Palmitoylcarnitine |
 | HMDB0000222 |
 |
C02990 |
 |
11953816 |
| Synonyms | Hexadecanoylcarnitine; |
| No. of studies | 25 |
|
Basic information |
| Metabolite name | L-Palmitoylcarnitine |
| HMDB0000222 |
|
C02990 |
|
11953816 |
| Synonyms | Hexadecanoylcarnitine; |
| No. of studies | 25 |
|
Relationship between L-Palmitoylcarnitine and depression (count: 25) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M087 | Type2 | ketamine group 2-h vs. baseline | Plasma | Human | Up |
| Study M1021 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | Serum | ICR mouse | Up |
| Study M1072 | Type1 | CUMS group vs. control group | Intestine | Cynomolgus monkey | Up |
| Study M1090 | Type1 | CUMS group vs. control group | Plasma | BALb/c mouse | Down |
| Study M1093 | Type1 | CSDS group vs. control group | Serum | C57BL/6N mouse | Down |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Up |
| Study M454 | Type1 | vascular depression model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M454 | Type2 | vascular depression model + YXST group vs. vascular depression model group | Hippocampus | ICR mouse | Up |
| Study M457 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M457 | Type2 | CUMS + D6 doses of PBR group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M457 | Type3 | D6 doses of PBR group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M541 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M541 | Type2 | CUMS + high dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M550 | Type2 | CUMS + GTD group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M587 | Type2 | MDD group, after 8-week SSRI treatment vs. before treatment | Plasma | Human | Down |
| Study M604 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M604 | Type2 | CUMS + PBR group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M608 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M608 | Type2 | CUMS + Poria cocos group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M613 | Type2 | CSDS susceptible + imipramine group vs. CSDS + vehicle group | Nucleus accumbens | C57BL/6 J mouse | Up |
| Study M648 | Type1 | ART-treated HIV with depressive symptom group vs. ART-treated HIV without depressive symptom group, validation cohort | Plasma | Human | Down |
| Study M648 | Type1 | ART-treated HIV with depressive symptom group vs. ART-treated HIV without depressive symptom group, discovery cohort | Plasma | Human | Down |
| Study M689 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M691 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M691 | Type2 | CUMS + low dose of Chaihu-Baishao group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M691 | Type2 | CUMS + low dose of Baishao group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M741 | Type2 | MDD group, post vs. before SSRI treatment | Plasma | Human | Down |
| Study M769 | Type1 | CSDS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M775 | Type1 | prenatal stress group vs. control group | Brain | Swiss Webster mouse | Down |
| Study M846 | Type2 | postpartum depression model + 919 syrup group vs. postpartum depression model group | Hippocampus | BALB/c mouse | Down |
| Study M870 | Type1 | CRS group vs. control group | Brain | C57BL/6 mouse | Up |
| Study M870 | Type2 | CRS + middle dose of Jia Wei Xiao Yao San group vs. CRS group | Brain | C57BL/6 mouse | Down |
| Study M870 | Type2 | CRS + sertraline group vs. CRS group | Brain | C57BL/6 mouse | Down |
| Study M940 | Type1 | CUMS group vs. control group | Cerebral cortex | Sprague-Dawley rat | Up |
| Study M947 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M947 | Type2 | CUMS + high dose of Chaigui granules group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M947 | Type2 | CUMS + middle dose of Chaigui granules group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |